Thrombosis Research

Article	Citations
Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)	197
Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis	179
D-dimer level is associated with the severity of COVID-19	153
Anticoagulation and bleeding risk in patients with COVID-19	94
Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19	86
Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave	85
Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia	76
Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome	75
Pulmonary embolism in hospitalised patients with COVID-19	75
Incidence of venous and arterial thromboembolic complications in COVID-19: A systematic review and meta-analysis	75
Mechanisms of thrombosis and cardiovascular complications in COVID-19	74
COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?	69
Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?	67
Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review	60
COVID-19 and thrombotic microangiopathies	59
In vitro hemocompatibility testing of medical devices	57
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies	55
Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients	55
Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19	53
Genetically predicted obesity and risk of deep vein thrombosis	51
Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study	50
D-dimer cut-off points and risk of venous thromboembolism in adult hospitalized patients with COVID-19	50
Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management	48
Pulmonary infarction in acute pulmonary embolism	48
Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination	48

Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis	46
Prevalence and characteristics of pulmonary embolism in 1042 COVID-19 patients with respiratory symptoms: A nested case-control study	44
Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study	43
Covid-19 associated autoimmune thrombotic thrombocytopenic purpura: Report of a case	42
Incidence and mortality due to thromboembolic events during the COVID-19 pandemic: Multi-sourced population-based health records cohort study	40
Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19	40
The effect of anticoagulation on clinical outcomes in novel Coronavirus (COVID-19) pneumonia in a U.S. cohort	40
Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis	39
Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action	38
COVID-19 and thrombosis: The role of hemodynamics	38
Lemierre syndrome: Current evidence and rationale of the Bacteria-Associated Thrombosis, Thrombophlebitis and LEmierre syndrome (BATTLE) registry	37
Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia	36
COVID-19 versus HIT hypercoagulability	36
Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vaccination	36
Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study	35
Higher procoagulatory potential but lower DIC score in COVID-19 ARDS patients compared to non-COVID-19 ARDS patients	34
COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy	31
Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: A retrospective study	31
Prediction models for recurrence and bleeding in patients with venous thromboembolism: A systematic review and critical appraisal	30
Management of venous thromboembolism in pregnancy	30
Efficacy and safety of a 12-week outpatient pulmonary rehabilitation program in Post-PE Syndrome	30
Thrombotic risk in children with COVID-19 infection: A systematic review of the literature	29
Venous thromboembolic events in the setting of extracorporeal membrane oxygenation support in adults: A systematic review	29
Pulmonary embolism and deep vein thrombosis: Similar but different	29
Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infection	28
The use of prophylaxis in the treatment of rare bleeding disorders	28
Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system	28
Is bivalirudin an alternative anticoagulant for extracorporeal membrane oxygenation (ECMO) patients? A systematic review and meta-analysis	28
Blocking podoplanin inhibits platelet activation and decreases cancer-associated venous thrombosis	27
Timing of venous thromboembolism diagnosis in hospitalized and non-hospitalized patients with COVID-19	27
The domino effect triggered by the tethered ligand of the protease activated receptors	27
Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease	27
The antithrombotic effect of caffeic acid is associated with a cAMP-dependent pathway and clot retraction in human platelets	26
ADAMTS 13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19	26
Links between thrombosis and inflammation in traumatic brain injury	26
The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants	26
Thrombotic thrombocytopenic purpura (TTP) after COVID-19 vaccination: A systematic review of reported cases	25
Bacterial outer membrane vesicles induce disseminated intravascular coagulation through the caspase-11-gasdermin D pathway	25
Management of high-risk pulmonary embolism in pregnancy	25
Tissue factor in COVID-19-associated coagulopathy	25
Platelet-leukocyte crosstalk in COVID-19: How might the reciprocal links between thrombotic events and inflammatory state affect treatment strategies and disease prognosis?	24
Diverse thrombus composition in thrombectomy stroke patients with longer time to recanalization	24
Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study	24
Association between neutrophil extracellular traps (NETs) and thrombosis in antiphospholipid syndrome	24
Recombinant human DNase I for the treatment of cancer-associated thrombosis: A pre-clinical study	23
Heavy menstrual bleeding in women on oral anticoagulants	23
Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit	23
Role of upfront CT pulmonary angiography at admission in COVID-19 patients	22
Rotational thromboelastometry to assess hypercoagulability in COVID-19 patients	22
Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection	22

Testosterone replacement therapy and the risk of venous thromboembolism: A systematic review and meta-analysis of randomized controlled trials	22
Determinants of plasma fibrin clot lysis measured using three different assays in healthy subjects	21
Four cases of acquired hemophilia A following immunization with mRNA BNT162b2 SARS-CoV-2 vaccine	21
Extended half-life recombinant products in haemophilia clinical practice – Expectations, opportunities and challenges	21
Deaths related to pulmonary embolism and cardiovascular events before and during the 2020 COVID-19 pandemic: An epidemiological analysis of data from an Italian high-risk area	21
Prevalence of aPhosphatidylserine/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: A systematic review and meta-analysis	21
Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis	20
Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: A systematic review and meta-analysis	20
The role of P-selectin in cancer-associated thrombosis and beyond	20
Extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: A systematic review and meta-analysis of the literature	19
Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors	19
Cancer-associated non-bacterial thrombotic endocarditis	19
How we make an accurate diagnosis of von Willebrand disease	19
Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes	19
Three-month follow-up of pulmonary embolism in patients with COVID-19	19
Immature platelets: a review of the available evidence	19
Risk of VTE associated with PORTs and PICCs in cancer patients: A systematic review and meta-analysis	19
Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy	19
High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score	19
Markers of NET formation and stroke risk in patients with atrial fibrillation: association with a prothrombotic state	19
Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes	18
Utility of D-dimers and intermediate-dose prophylaxis for venous thromboembolism in critically ill patients with COVID-19	18
One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: Results from the Cancer-VTE Registry	18
Low admission protein C levels are a risk factor for disease worsening and mortality in hospitalized patients with COVID-19	18
Preoperative and intraoperative predictors of deep venous thrombosis in adult patients undergoing craniotomy for brain tumors: A Chinese single-center, retrospective study	18
A nomogram model to predict the venous thromboembolism risk after surgery in patients with gynecological tumors	18
Translating the success of prophylaxis in haemophilia to von Willebrand disease	18
Developing and validating natural language processing algorithms for radiology reports compared to ICD-10 codes for identifying venous thromboembolism in hospitalized medical patients	18
Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: A systematic review and meta-analysis	17
Development and prospective validation of a novel risk score for predicting the risk of lower extremity deep vein thrombosis among multiple trauma patients	17
Rise of levels of von Willebrand factor and factor VIII with age: Role of genetic and acquired risk factors	17
How I treat von Willebrand disease	17
Oral contraceptives and hormone replacement therapy: How strong a risk factor for venous thromboembolism?	17
Validation of the PLASMIC score for predicting ADAMTS13 activity <10% in patients with suspected thrombotic thrombocytopenic purpura in Alberta, Canada	17
Anticoagulation in COVID-19 patients – An updated systematic review and meta-analysis	17
Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis	17
Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era	17
Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies	16
Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism – The COSIMO study	16
The prevalence of pulmonary embolism in patients with COVID-19 and respiratory decline: A three-setting comparison	16
Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance	16
Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia	16
Lifestyle factors and venous thromboembolism in two cohort studies	16
The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome	16
Neutrophil extracellular traps and cancer-associated thrombosis	16
NLRP3 inflammasome contributes to endotoxin-induced coagulation	16
Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and meta-analysis	16
Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE	16
Current estimates of the incidence of acute venous thromboembolic disease in Canada: A meta-analysis	16
Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability	16
Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity	15
A comparison of natural language processing to ICD-10 codes for identification and characterization of pulmonary embolism	15
Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms	15
Longitudinal multiparametric characterization of platelet dysfunction in COVID-19: Effects of disease severity, anticoagulation therapy and inflammatory status	15
Pulmonary embolism: Age specific temporal trends in incidence and mortality in Denmark 1999–2018	15
Risk of symptomatic venous thromboembolism in mild and moderate COVID-19: A comparison of two prospective European cohorts	15
Reduced intracellular antioxidant capacity in platelets contributes to primary immune thrombocytopenia via ROS-NLRP3-caspase-1 pathway	15
ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis	14
Prediction of hypofibrinogenemia and thrombocytopenia at the point of care with the Quantra® QPlus® System	14
Differences in the biochemical composition of three plasma derived human fibrinogen concentrates	14
Increased levels of platelet-derived microparticles in pulmonary hypertension	14
COVID-19 risk perceptions, worries and preventive behaviors in patients with previous pulmonary embolism	14
Knockdown of liver-derived factor XII by GalNAc-siRNA ALN-F12 prevents thrombosis in mice without impacting hemostatic function	14
Comparison of absolute immature platelet count to the PLASMIC score at presentation in predicting ADAMTS13 deficiency in suspected thrombotic thrombocytopenic purpura	14
Cancer and stroke: What do we know and where do we go?	14
Biomarker association with cardiovascular disease and mortality – The role of fibrinogen. A report from the NHANES study	14
The effect of race on composite thrombotic events in patients with COVID-19	14
Antisense oligonucleotides and nucleic acids generate hypersensitive platelets	14
Coagulation factors XI and XII as possible targets for anticoagulant therapy	14
Erythrocytosis and thromboembolic events in transgender individuals receiving gender-affirming testosterone	14
The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin	14
Splanchnic vein thrombosis associated with myeloproliferative neoplasms	14
“Whole life changed” - Experiences of how symptoms derived from acute pulmonary embolism affects life. A qualitative interview study	14
Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopenia	14
Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model	14
Incidence and prevalence of venous thromboembolism in Norway 2010–2017	14
Pharmacokinetics of enoxaparin in COVID-19 critically ill patients	14
Associations between hemostatic markers and mortality in COVID-19 – Compounding effects of D-dimer, antithrombin and PAP complex	14
Multiparameter microfluidics assay of thrombus formation reveals increased sensitivity to contraction and antiplatelet agents at physiological temperature	13
Upregulation of mechanosensitive channel Piezo1 involved in high shear stress-induced pulmonary hypertension	13

Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial	13
Real-world experience with reversal of dabigatran by idarucizumab	13
Can anticoagulants improve the survival rate for patients with idiopathic pulmonary arterial hypertension? A systematic review and meta-analysis	13
Brain-derived extracellular vesicles mediated coagulopathy, inflammation and apoptosis after sepsis	13
Coronavirus disease 2019 is associated with catheter-related thrombosis in critically ill patients: A multicenter case-control study	13
Coagulation parameters and venous thromboembolism in patients with and without COVID-19 admitted to the Emergency Department for acute respiratory insufficiency	13
COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic	13
Influence of sex on development of thrombosis in patients with COVID-19: From the CLOT-COVID study	13
Extensive pulmonary perfusion defects compatible with microthrombosis and thromboembolic disease in severe Covid-19 pneumonia	13
Differential procoagulatory response of microvascular, arterial and venous endothelial cells upon inflammation in vitro	13
Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy	13
COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets	13
Applying rigorous eligibility criteria to studies evaluating prognostic utility of serum biomarkers in pulmonary embolism: A systematic review and meta-analysis	12
The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE	12
Thrombotic risk in secondary polycythemia resembles low-risk polycythemia vera and increases in specific subsets of patients	12
Associations of NETs with inflammatory risk and atherosclerotic severity in ST-segment elevation myocardial infarction	12
Depression and anxiety up to two years after acute pulmonary embolism: Prevalence and predictors	12
Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial	12
Persistent circulating platelet and endothelial derived microparticle signature may explain on-going pro-thrombogenicity after acute coronary syndrome	12
Genetic and molecular evidence for complement dysregulation in patients with HELLP syndrome	12
Congenital (hypo-)dysfibrinogenemia and bleeding: A systematic literature review	12
Frequency and incidence of arterial events in patients with venous thromboembolism compared to the general population: A systematic review and meta-analysis of cohort studies	12
Coagulation activation during extracorporeal membrane oxygenation (ECMO)	12
Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration	12
Effectiveness and safety of extended thromboprophylaxis in post-discharge patients with COVID-19: A systematic review and meta-analysis	12
Updated hospital associated venous thromboembolism outcomes with 90-days follow-up after hospitalisation for severe COVID-19 in two UK critical care units	12
Association between Covid-19 and Pulmonary Embolism (AC-19-PE study)	12
Catheter related thrombosis in hospitalized infants: A neural network approach to predict risk factors	12
Incidence and risk factors of venous thromboembolism in men and women	12
A new hybrid immunocapture bioassay with improved reproducibility to measure tissue factor-dependent procoagulant activity of microvesicles from body fluids	12
Incidence, timing and risk factors of venous thromboembolic events in patients with pancreatic cancer	12
36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE	12
More evidence available for the use of Bivalirudin in patients supported by extracorporeal membrane oxygenation	12
Determinants of left atrial thrombus or spontaneous echo contrast in nonvalvular atrial fibrillation	12
Right ventricular stroke distance predicts death and clinical deterioration in patients with pulmonary embolism	12
Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial	12
Antithrombin deficiency: A pediatric disorder	12
Coagulation disorders in Chagas disease: A pathophysiological systematic review and meta-analysis	12
Impact of the circadian clock on fibrinolysis and coagulation in healthy individuals and cardiovascular patients – A systematic review	12
Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning	11
The role of platelets in heat-related illness and heat-induced coagulopathy	11
Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection	11
Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism	11
Possible immune regulation mechanisms for the progression of chronic thromboembolic pulmonary hypertension	11
Pleiotropic effects of PCSK9-inhibition on hemostasis: Anti-PCSK9 reduce FVIII levels by enhancing LRP1 expression	11
Anticoagulation in COVID-19: Randomized trials should set the balance between excitement and evidence	11
Women with inherited bleeding disorders – Challenges and strategies for improved care	11
Bleeding related to oral anticoagulants: Trends in US emergency department visits, 2016-2020	11
Arthropathy in people with mild haemophilia: Exploring risk factors	11
The incidence of thrombotic events with idarucizumab and andexanet alfa: A systematic review and meta-analysis	11
Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer	11
Step up to the platelet: Role of platelets in inflammation and infection	11
JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis	11
Immature platelet dynamics correlate with ADAMTS13 deficiency and predict therapy response in immune-mediated thrombotic thrombocytopenic purpura	11
Stroke mortality in cancer survivors: A population-based study in Japan	11
Clinical and laboratory diagnosis of rare coagulation disorders (RCDs)	11
Strategies for improving guideline adherence of anticoagulants for patients with atrial fibrillation in primary healthcare: A systematic review	11
A novel interaction between extracellular vimentin and fibrinogen in fibrin formation	11
Platelet ageing: A review	11
Decreased protein C activity, lower ADAMTS13 antigen and free protein S levels accompanied by unchanged thrombin generation potential in hospitalized COVID-19 patients	11
Thrombin generation assay as a biomarker of cardiovascular outcomes and mortality: A narrative review	11
Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trial	11
Anticoagulation therapy in COVID-19: Is there a dose-dependent benefit?	10
In situ pulmonary thrombosis in patients with COVID-19 pneumonia: different phenotypes may exist	10
The optimal regimen, efficacy and safety of tranexamic acid and aminocaproic acid to reduce bleeding for patients after total hip arthroplasty: A systematic review and Bayesian network meta-analysis	10
Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: Hemostatic and thrombotic outcomes	10
Heparin-induced thrombocytopenia and thrombosis in a patient with Covid-19	10
Neutrophil extracellular traps: A novel therapeutic target for intracranial hemorrhage	10
Prognostic role of serial electrocardiographic changes in patients with acute pulmonary embolism. Data from the Italian Pulmonary Embolism Registry	10
Lower limb deep vein thrombosis in COVID-19 patients admitted to intermediate care respiratory units	10
Thromboprophylaxis for orthopedic surgery; An updated meta-analysis	10
Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic	10
Elevated plasma D-dimer levels are associated with risk of future incident venous thromboembolism	10
Contemporary trends in mortality related to high-risk pulmonary embolism in US from 1999 to 2019	10
Detection of anti-GPIbα autoantibodies in a case of immune thrombocytopenia following COVID-19 vaccination	10
Treatment of catheter-related thrombosis in patients with hematologic malignancies: A Venous thromboEmbolism Network U.S. retrospective cohort study	10
Pulmonary embolism in patients with COVID-19 pneumonia: When we have to search for it?	10
Heparin failure and COVID-19: Should we explore other anticoagulants? An observational report regarding in-vitro recovery of anticoagulant action in COVID-19 patients in intensive care	10
Venous thromboembolism in patients hospitalised with COVID-19 in England	10
Is it hyperfibrinolysis or fibrinolytic shutdown in severe COVID-19?	10
Development and validation of a predictive score for venous thromboembolism in newly diagnosed non-small cell lung cancer	10
Diagnostic accuracy of four different D-dimer assays: A post-hoc analysis of the YEARS study	10
HMGB1 is increased in patients with immune thrombocytopenia and negatively associates with Tregs	9
Coronavirus disease 2019 (COVID-19) associated coagulopathy and its impact on outcomes in Shenzhen, China: A retrospective cohort study	9
Venous thromboembolism after fast-track elective revision hip and knee arthroplasty – A multicentre cohort study of 2814 unselected consecutive procedures	9
Increased prevalence of heparin induced thrombocytopenia in COVID-19 patients	9
Cardiac and vascular features of arterial and venous primary antiphospholipid syndrome. The multicenter ATHERO-APS study	9
Massive external validation of a machine learning algorithm to predict pulmonary embolism in hospitalized patients	9
Identification of the antithrombotic protein S as a potential target of the SARS-CoV-2 papain-like protease	9
Quantitative analysis of clot density, fibrin fiber radius, and protofibril packing in acute phase myocardial infarction	9
Long-term adherence to direct acting oral anticoagulants and the influence of health beliefs after switching from vitamin-K antagonists: Findings from the Switching Study	9
Anticoagulation management and related outcomes in patients with cancer-associated thrombosis and thrombocytopenia: A systematic review and meta-analysis	9
Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy	9
Sulfated non-anticoagulant low molecular weight heparin in the prevention of cancer and non-cancer associated thrombosis without compromising hemostasis	9
Characterizing the use of anticoagulants in children using the American Thrombosis and Hemostasis Network Dataset (ATHNdataset)	9